Biogen reports positive signs from early study of tau-lowering drugnews2023-10-25T14:50:33+00:00October 25th, 2023|Endpoints News|
Merck ends PhII trials of Alzheimer’s and depression small molecule after liver toxicity observationsnews2023-10-25T14:47:24+00:00October 25th, 2023|Endpoints News|
How Bristol Myers’ buyout offer for Mirati dwindled by billions of dollarsnews2023-10-25T14:46:36+00:00October 25th, 2023|Endpoints News|
Danaher’s third-quarter revenue from biotech services down 19% amid slowdown in China, USnews2023-10-25T11:20:46+00:00October 25th, 2023|Endpoints News|
DermBiont raises $35.2M Series B to advance two topical skin drugs through PhIInews2023-10-25T10:51:18+00:00October 25th, 2023|Endpoints News|
Grifols Alzheimer’s vaccine appears safe, but efficacy unclear, in PhII studynews2023-10-24T22:31:05+00:00October 24th, 2023|Endpoints News|
FDA expected to decide on AstraZeneca’s self-administered flu vaccine next quarternews2023-10-24T19:13:37+00:00October 24th, 2023|Endpoints News|
Samsung adds another Lucentis interchangeable biosimilar to the mixnews2023-10-24T19:07:11+00:00October 24th, 2023|Endpoints News|
Biogen, GSK, Novo Nordisk named in Time’s best inventions of 2023 listnews2023-10-24T18:49:05+00:00October 24th, 2023|Endpoints News|
Form 483 for UCB’s Swiss site notes deficiencies in quality control operationsnews2023-10-24T18:42:27+00:00October 24th, 2023|Endpoints News|
